Introduction
DuP 721 and DuP 105 are new synthetic antibacterials of the oxazolidinone series. The chemical structure and chemical name of each compound is shown in Figure 1 . The oxazolidinones were discovered to have antibacterial activity during systematic screening studies of new drugs . This new class of compounds is unrelated to any currently available antimicrobial agent. Preliminary studies have suggested that the compounds are active in vitro and in vivo against staphylococci and enterococci and that they exert their antibacterial effect through inhibition of bacterial protein synthesis . In addition DuP 721 appears to have in-vitro activity against Mycobacterium tuberculosis (Stottmeier, 1987) . The compounds are orally absorbed in animals (Daly et al., 1987) . In addition, DuP 105 is water soluble and has potential for use by either the oral or the intravenous route.
In this study, we describe the in-vitro antibacterial spectrum of DuP 721 and DuP 105 in comparison with several currently available oral and intravenous antibacterial agents. The mechanism of action of the compounds was explored by examining their effects on protein synthesis in an isolated ribosome preparation. 
Methods

Bacterial strains
The bacterial strains used in this study were unique clinical isolates collected at the New England Deaconess and Massachusetts General Hospitals, Boston, MA, with the exception of the penicillin-resistant pneumococci and viridans streptococci which had been collected in South Africa (Jacobs et al., 1978; Eliopoulos, Gardella & Moellering, 1982) . The Legionella strains comprised L. pneumophila (17), L. longbeachae (2), and one each of L. bozemanii, L. micdadei, and L. dumoffii.
Antimicrobial agents and chemicals
Standard antimicrobial reference powders were obtained from the following sources: DuP 105 and DuP 721, E.I. duPont de Nemours & Co., Indianapolis, IN; ciprofloxacin, Miles Pharmaceuticals, West Haven, CT; clindamycin, The Upjohn Co., Kalamazoo, MI; oxacillin, Bristol Laboratories, Syracuse, NY; penicillin, Squibb, Princeton, NJ. All antibiotic solutions were prepared on the day of use. Antibiotic containing discs were obtained from BBL Microbiology Systems, Cockeysville, MD (BBL) or made with standard powders and blank discs (BBL).
Agar dilution susceptibility studies
Susceptibility testing was performed by a standard agar dilution technique (Washington, 1985) using Mueller-Hinton agar (BBL) (MHA), which was supplemented with 5% defibrinated sheep blood when testing streptococci. Inocula of approximately 10* cfu were applied to plates with a 32-prong inoculating device. 
Time kill studies
Limited time-kill studies with Staph. aureus ATCC 29213 were performed in MHB using dilutions of overnight cultures to obtain 10* cfu/ml in 10-ml volumes of broth. Flasks were incubated without agitation and colony counts were performed in duplicate at 0, 4 and 24 h.
Selection of resistant organisms
The method of Tenney, Maack & Chippendale (1983) was used to determine whether colonies resistant to DuP 105 or DuP 721 could be selected. Briefly, heavy inocula of Staph. aureus ATCC 29213 or Str.faecalis E-l were applied to MHA and Brain Heart Infusion (BHI) (Gibco) plates containing DuP 105 or DuP 721 at a concentration equal to one-half the MIC. Colonies arising after 72 h incubation at 37°C were then serially transferred to plates containing two-fold incremental concentrations of the drug until a concentration was reached that prevented further growth. The stability of resistance determined by this method was studied after passage of strains on antimicrobial-free medium. The frequency of resistant subpopulations or of single-step mutations was assessed by application of 10 9 cfu to plates containing DuP 721 or DuP 105 at four times the MIC.
Interactions with other compounds
The potential for synergism or antagonism with other antibacterials was examined by a disc approximation technique similar to that used to detect antagonism between /Mactam agents (Sanders & Sanders, 1979) . Discs containing 100 fig DuP 105 were prepared by saturating blank paper discs (BBL) with 33 /d of a 3 mg/ml solution of DuP 105 in water; discs containing 30 /ig DuP 721 were prepared similarly with 20 yH of a 1-5 mg/ml solution of DuP 721 in acetone. The drug content of the discs was arbitrarily chosen to yield generous, easily measurable zone sizes against test organisms. The discs were dried overnight and kept at -20°C until use. Discs for other antibiotics were obtained commercially (BBL or antibiotic manufacturer). Mueller-Hinton agar plates were streaked with log phase cultures of test organisms (Staph. aureus ATCC 29213 and Escherichia coli ATCC 25922) diluted to approximately 10 6 cfu/ml and drug discs were placed at distances between 15 and 30 mm apart on the inoculated plates. Zone sizes and interactions between compounds were measured after overnight incubation at 37°C in air.
Studies of ribosomal protein synthesis
The direct effect of DuP 105 and DuP 721 on protein synthesis in ribosomes prepared from a clinical strain of Str. faecalis was assessed in a cell-free system by the method of Nirenberg (1964) with minor modifications as described by Farber et al. (1983) . Ribosomal protein synthesis was measured by using [ 
Results
Susceptibility studies
Results of agar dilution susceptibility studies are shown in Table I . DuP 721 was equally active against staphylococci, streptococci, and enterococci with MIC 90 s of 2-4 mg/1. There was no difference in activity against methicillin-resistant and methicillin-susceptible staphylococci and only a two-fold difference in activity against penicillin-susceptible compared with penicillin-resistant viridans streptococci and against Str. faecalis compared with Str.faecium. DuP 105 was generally four-fold less active than DuP 721. Neither compound had activity against Gram-negative facultative bacilli; MICs were between 256 and 1000 mg/1 for these organisms. There was no significant difference in MIC values when DPA was used instead of MHA. Against 19 strains of B.fragilis the MIC^, of DuP 721 was 16 mg/1; against Legionella spp., the MIC 90 was 64 mg/1 for both drugs. DuP 105 had little activity against 22 strains of Campylobactor jejuni with an MIC^o of 128 mg/1. The results of broth dilution MIC/MBC determinations are given in Table II . Both DuP 721 and DuP 105 displayed primarily bacteriostatic activity at an inoculum of 10 6 cfu/ml against the strains tested, although both drugs had bactericidal activity against a strain of Staph. epidermidis. In a limited time kill study against Staph. aureus ATCC 25913, both compounds had only bacteriostatic activity (Figure 2) .
Selection of resistant organisms
No resistant colonies of Staph. aureus could be selected by stepwise passage on MHA agar plates containing two-fold incremental concentrations of DuP 105 or DuP 721. However, with serial passage on incremental concentrations of DuP 105 in brain heart infusion agar colonies of Str. faecalis resistant to levels as high as 64 mg/1 (four-fold higher than original isolate) could be selected. This faint haze of growth required 72 h incubation for detection and the resulting colonies returned to baseline susceptibility after passage in drug-free agar. No resistant colonies were noted when a high inoculum (10 9 cfu) of Str. faecalis or Staph. aureus was applied to agar containing either drug at four times the MIC. no zone of inhibition against E. coli by either compound. In our earlier studies with another oxazolidinone, S-6123, we found evidence for antagonism of the antibacterial effect of the quinolones by the new compound (Daly et al., 1987) . Against Staph. aureus both DuP 105 and DuP 721 antagonized the inhibitory activities of ciprofloxacin and norfloxacin, decreasing the radii of zones of inhibition from 16 to 12 mm and from 14-5 to 9 mm respectively when these discs were placed 22 mm apart. There was evidence of synergism between ciprofloxacin and the oxazolidines against E. coli ATCC 25922 with an increase of the zone radius of DuP 105 from no zone of inhibition to 8 mm and of Dup 721 from no zone to 6 mm when the discs were placed 22 mm apart; a similar effect was seen with norfloxacin.
Interactions with other compounds
Studies of ribosomal protein synthesis
Dup 105 and Dup 721 inhibited protein synthesis at the ribosomal level (Figure 3) . Addition of either Dup 105 or DuP 721 to the ribosomal preparation resulted in up to a 96% decrease in polyuridylic acid-directed synthesis of polyphenylalanine in the cell free system.
Discussion
The oxazolidinone compounds, DuP 721 and DuP 105, were active mainly against Gram-positive bacteria. The activity of DuP 721 paralleled the activity of vancomycin and ciprofloxacin against most of the Gram-positive cocci, although against certain species the new drug was somewhat less active. In general, DuP 721 was approximately four-fold more active than its water soluble analogue, DuP 105. The activity of each drug was greater than or equal to that of cephalexin, another oral drug, against all the Gram-positive cocci tested with the exception of the /J-haemolytic streptococci, against which cephalexin was significantly more active than DuP 105. In animals, peak serum concentrations of DuP 721 after oral dosing exceed the MIC 9O s for most Gram-positive cocci suggesting that these oxazolidinones might be useful in the treatment of infections caused by these organisms, including methicillin-resistant Staph. aureus. In a rat model, high concentrations of a similar oxazolidinone (S-6123) were achieved in the urine after a single oral dose (Daly et al., 1987) , suggesting that these drugs might also be useful in the treatment of urinary tract infections, including those caused by enterococci.
Both DuP 105 and DuP 721 were primarily bacteriostatic in vitro. Both compounds appeared to exert their antibacterial effect by inhibition of protein synthesis. Our previous work with a prototype compound demonstrated a similar inhibition of bacterial protein synthesis, with no significant effect on DNA or RNA synthesis (Daley et al., 1987) .
It does not appear that there is cross resistance between the new agents and commonly used antimicrobials such as /J-lactam agents or clindamycin. In addition, development of resistance to the drugs during therapy should not be a major problem since it was difficult in vitro to select organisms with stable resistance to the compounds.
Further study of the antimicrobial spectrum, toxicity, pharmacokinctics, mechanism of action and interactions with other compounds of the oxazolidinone class of antibacterials is warranted.
